Flex Pharma Inc News Releases http://ir.flex-pharma.com/ Flex Pharma Inc News Releases en Flex Pharma Announces Broker Authority to Vote on Certain Proposals http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-announces-broker-authority-vote-certain-proposals BOSTON --(BUSINESS WIRE)--Jun. 25, 2019-- Flex Pharma, Inc. (Nasdaq: FLKS) today announced that on or about June 27, 2019 it will mail a supplement (the “Supplement”) to its proxy materials to provide stockholders with updated information regarding brokers’ discretionary authority to vote Tue, 25 Jun 2019 07:00:00 -0400 Flex Pharma Inc News Releases 8986 Flex Pharma Announces Overwhelming Support to Date for the Proposed Merger with Salarius Pharmaceuticals but More Votes are Needed to Complete the Merger http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-announces-overwhelming-support-date-proposed-merger - Special Meeting of Stockholders Adjourned Until July 12, 2019 BOSTON --(BUSINESS WIRE)--Jun. 17, 2019-- Flex Pharma, Inc. (Nasdaq: FLKS) today announced that approximately 85% of shares voted to date support the proposed merger with Salarius Pharmaceuticals, LLC , an epigenetic oncology company. Mon, 17 Jun 2019 07:00:00 -0400 Flex Pharma Inc News Releases 8971 Flex Pharma Announces that ISS and Glass Lewis Recommend Shareholders Vote “FOR” All Agenda Items relating to Flex’s Strategic Merger with Salarius Pharmaceuticals http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-announces-iss-and-glass-lewis-recommend-shareholders BOSTON --(BUSINESS WIRE)--Jun. 10, 2019-- Flex Pharma, Inc. (Nasdaq: FLKS) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis recommend that shareholders vote FOR all agenda items before or at Flex Pharma’s June 14 Special Shareholders Meeting. Mon, 10 Jun 2019 07:00:00 -0400 Flex Pharma Inc News Releases 8946 Flex Pharma Reports First Quarter 2019 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-first-quarter-2019-financial-results BOSTON --(BUSINESS WIRE)--May 1, 2019-- Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended March 31, 2019 . On January 3, 2019 , Flex Pharma (the "Company") and Salarius Pharmaceuticals, LLC ("Salarius") entered into an Agreement and Plan of Merger Wed, 01 May 2019 07:00:00 -0400 Flex Pharma Inc News Releases 8886 Flex Pharma Reports Fourth Quarter and Fiscal 2018 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-fourth-quarter-and-fiscal-2018-financial BOSTON --(BUSINESS WIRE)--Mar. 6, 2019-- Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months and fiscal year ended December 31, 2018 . On January 3, 2019 , Flex Pharma (the "Company") and Salarius Pharmaceuticals, LLC ("Salarius") entered into an Agreement Wed, 06 Mar 2019 07:00:00 -0500 Flex Pharma Inc News Releases 8831 Flex Pharma and Salarius Pharmaceuticals Announce Merger Agreement to Accelerate Clinical Development of Novel Epigenetic Therapy for Cancer http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-and-salarius-pharmaceuticals-announce-merger – Lead Candidate in Clinical Trial for Treating Ewing Sarcoma – – Salarius Completes $6.4 Million Private Placement – – Conference Call and Live Audio Webcast Scheduled for Today at 9:00 a.m. ET – BOSTON & HOUSTON --(BUSINESS WIRE)--Jan. 4, 2019-- Flex Pharma, Inc . Fri, 04 Jan 2019 07:00:00 -0500 Flex Pharma Inc News Releases 8776 Flex Pharma Reports Third Quarter 2018 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-third-quarter-2018-financial-results BOSTON --(BUSINESS WIRE)--Nov. 5, 2018-- Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended September 30, 2018 . On June 13, 2018 , the Company announced that it was ending its ongoing Phase 2 clinical trial investigations of FLX-787 in Motor Neuron Mon, 05 Nov 2018 07:00:00 -0500 Flex Pharma Inc News Releases 8726 Flex Pharma Reports Second Quarter 2018 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-second-quarter-2018-financial-results BOSTON --(BUSINESS WIRE)--Aug. 1, 2018-- Flex Pharma, Inc . (NASDAQ: FLKS), today announced its financial results for the three months ended June 30, 2018 . On June 13, 2018 , the Company announced that it was ending its ongoing Phase 2 clinical trial investigations of FLX-787 in Motor Neuron Wed, 01 Aug 2018 07:00:00 -0400 Flex Pharma Inc News Releases 8666 Flex Pharma Announces Corporate Update http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-announces-corporate-update -- FLX-787 Phase 2 Clinical Programs in ALS & CMT to Close -- -- FLX-787 Clinical Evaluation of Dysphagia to Continue -- -- Wedbush PacGrow Retained to Guide Assessment of Strategic Alternatives -- -- Restructuring with Workforce Reduction -- BOSTON --(BUSINESS WIRE)--Jun. Wed, 13 Jun 2018 07:00:00 -0400 Flex Pharma Inc News Releases 8601 Flex Pharma Reports First Quarter 2018 Financial Results http://ir.flex-pharma.com/news-releases/news-release-details/flex-pharma-reports-first-quarter-2018-financial-results -- Positive Anti-Cramping Effect of FLX-787 Reported in Recent MS study -- -- FLX-787 Phase 2 ALS & CMT Clinical Studies Ongoing -- Conference Call Scheduled Today at 9:00 a.m. ET BOSTON --(BUSINESS WIRE)--May 2, 2018-- Flex Pharma, Inc . (NASDAQ: FLKS), a clinical-stage biotechnology company that Wed, 02 May 2018 07:00:00 -0400 Flex Pharma Inc News Releases 8581